Last reviewed · How we verify
NCT04481893: ThyroVir
Interest of the Virtual Reality Headset in the Management of Perioperative Stress in Patients Candidates for Total Thyroidectomy
NA trial testing Use of a virtual reality headset in Thyroid Cancer in 82 participants. Completed in 6 June 2025.
6 June 2025
Quick facts
| Lead sponsor | Centre Francois Baclesse |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 82 |
| Start date | 18 November 2020 |
| Primary completion | 6 June 2025 |
| Estimated completion | 6 June 2025 |
| Sites | 3 locations across France |
Drugs / interventions tested
- Use of a virtual reality headset
Conditions studied
- Thyroid Cancer — all drugs for Thyroid Cancer →
- Thyroidectomy — all drugs for Thyroidectomy →
Sponsor
Centre Francois Baclesse — full company profile →
Who can join
18 and older, any sex, with Thyroid Cancer or Thyroidectomy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Study the interest of hypnosis techniques by virtual reality based on the use of a virtual reality headset with the AQUA® application on the reduction of pre-operative stress in patients candidates for total thyroidectomy
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04481893
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Thyroid Cancer
Currently open trials in the same condition.
- NCT07428057 — Postoperative Hypocalcemia After Thyroidectomy · recruiting
- NCT07370675 — Active Surveillance for Bethesda IV Thyroid Nodules · NA · recruiting
- NCT07389512 — Pharmaceutical Management in Targeted Radioligand Therapy · recruiting
- NCT07438847 — 177Lu-CTR-FAPI for the Treatment of Thyroid Cancer · Phase 1 · recruiting
- NCT07419932 — Response to Neoadjuvant Treatment in Locally Advanced Thyroid Cancer · recruiting
Other Centre Francois Baclesse trials
Trials by the same sponsor.
- NCT06959810 — Impact of Adapted Aesthetic Onco in Patients With Upper Aerodigestive Tract Cancer During Their Management · NA · recruiting
- NCT06792721 — MEASUREMENT OF CIRCULATING MUTATION BURDEN · recruiting
- NCT06817161 — Benefit of Transcutaneous Auricular Vagus Nerve Stimulation in Improving Quality of Life in First Line Treatment of Ovar · Phase 3 · recruiting
- NCT06612827 — Development of Tumor Organoids From Undifferentiated Primary Carcinomas to Guide Therapeutic Decisions · recruiting
- NCT06798922 — Flap Sparing in Postoperative Radiotherapy of Oral Cavity Cancers · Phase 3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04481893 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centre Francois Baclesse
- Last refreshed: 18 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04481893.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing